Efficacy of Second-Line Treatments in Lung and Extrapulmonary Neuroendocrine Carcinomas


Abstract views: 83 / PDF downloads: 44

Authors

  • Serdar ATA adana şehir hastanesi tıbbi onkoloji
  • Oğuzhan KESEN MD
  • Ahmet Ziya BAYHAN MD
  • Tolga KÖŞECİ MD
  • Zeynel Abidin TAŞ MD
  • Berna BOZKURT DUMAN Prof
  • Timuçin ÇİL Prof

DOI:

https://doi.org/10.5281/zenodo.8404432

Keywords:

Neuroendocrine tumors, Neuroendocrine carcinoma, Cisplatin-etoposide therapy, Second-line treatment, Ki-67 index

Abstract

Objective: The objective of this study was to explore the efficacy of second-line treatments, given the ambiguity surrounding subsequent treatments due to rapid disease progression and patient scarcity.

Materials & Methods: A retrospective study was conducted at the XXXX City Training and Research Hospital Medical Oncology Outpatient Clinic from 2017 to 2021, encompassing 991 patients diagnosed with lung cancer and NEC. Data from 304 patients, specifically diagnosed with NEC/Small-cell lung cancer, were analyzed. All patients underwent cisplatin-etoposide as their first-line treatment, with 35 of these receiving a second-line treatment.

Results: Of the analyzed patients, 91 were diagnosed with lung-derived-NEC and 35 with extrapulmonary-NEC. The median progression-free survival (PFS) post the first-line treatment was 7.4 months. A total of 35 patients received second-line chemotherapy. The median PFS2 was 5.1 months and 6.6 months in patients who received irinotecan-based chemotherapy and cisplatin-etoposide therapy, respectively(p:0.86).  There was no significant difference between patients with lung-derived-NEC and patients with extrapulmonary-NEC in PFS2 or OS values.

Conclusion: The study underscores the lack of a standardized second-line treatment for small-cell lung cancer. However, data suggests that cisplatin-etoposide therapy might be effective as a second-line treatment, especially for patients relapsing after more than six months post the initial treatment. The outcomes align with other research, indicating a decline in overall survival as the Ki-67 index value increases

Author Biographies

Oğuzhan KESEN, MD

Department of Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.

Ahmet Ziya BAYHAN, MD

Department of Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.

Tolga KÖŞECİ, MD

Department of Medical Oncology, Faculty of Medicine, Çukurova University

Zeynel Abidin TAŞ, MD

Department of Pathology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey

Berna BOZKURT DUMAN, Prof

Department of Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey

Timuçin ÇİL, Prof

Department of Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey

References

de M Rêgo, J. F., Salles Scortegagna de Medeiros, R., Braghiroli, M. I., Galvão, B., Evangelista Bezerra Neto, J., Ramella Munhoz, R., … Riechelmann, R. P. (2017). Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.

Ecancermedicalscience, 11. https://doi.org/10.3332/ecancer.2017.767 Nöroendokrin tümörler, Nöroendokrin karsinom, Sisplatin-etoposid tedavisi, İkinci basamak tedavi, Ki-67 indeksi

Garcia-Carbonero, R., Sorbye, H., Baudin, E., Raymond, E., Wiedenmann, B., Niederle, B., … all other Vienna Consensus Conference participants. (2016). ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology, 103(2), 186–194. https://doi.org/10.1159/000443172

Hanna, N., Bunn, P. A., Langer, C., Einhorn, L., Guthrie, T., Beck, T., … Sandler, A. (2006). Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 24(13), 2038–2043. https://doi.org/10.1200/JCO.2005.04.8595

Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., … Liu, S. V. (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379(23), 2220–2229.

https://doi.org/10.1056/NEJMoa1809064

Klöppel, G., Heitz, P. U., Capella, C., & Solcia, E. (1996). Pathology and Nomenclature of Human Gastrointestinal Neuroendocrine (Carcinoid) Tumors and Related Lesions. World Journal of Surgery, 20(2), 132–141. https://doi.org/10.1007/s002689900021

La Rosa, S., & Uccella, S. (2020). Classification of neuroendocrine neoplasms: Lights and shadows. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-020-09612-2

Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., … Raspaud, C. (2015). Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial. Annals of Oncology, 26(5), 908–914. https://doi.org/10.1093/annonc/mdv065

Ramella Munhoz, R., de Mendonça Rego, J. F., de Celis Ferrari, A. R., Ignez Braghiroli, M., Mendonça Bariani, G., Marcelo Hoff, P., … Riechelmann, R. (2013). Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas. Rare

Tumors, 5(3), 135–139. https://doi.org/10.4081/rt.2013.e39

Sorbye, H., Welin, S., Langer, S. W., Vestermark, L. W., Holt, N., Osterlund, P., … Knigge, U. (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology, 24(1), 152–160. https://doi.org/10.1093/annonc/mds276

Strosberg, J. R., Coppola, D., Klimstra, D. S., Phan, A. T., Kulke, M. H., Wiseman, G. A., & Kvols, L. K. (2010). The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas.

Pancreas, 39(6), 799–800. https://doi.org/10.1097/MPA.0b013e3181ebb56f

Thomas, K. E. H., Voros, B. A., Boudreaux, J. P., Thiagarajan, R., Woltering, E. A., & Ramirez, R. A. (2019). Current Treatment Options in

Gastroenteropancreatic Neuroendocrine Carcinoma. The Oncologist, 24(8), 1076–1088. https://doi.org/10.1634/theoncologist.2018-0604

Walenkamp, A. M. E., Sonke, G. S., & Sleijfer, D. T. (2009). Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treatment Reviews, 35(3), 228–236. https://doi.org/10.1016/j.ctrv.2008.10.007

Yamaguchi, T., Machida, N., Morizane, C., Kasuga, A., Takahashi, H., Sudo, K., … Okusaka, T. (2014). Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Science, 105(9), 1176–1181. https://doi.org/10.1111/cas.12473

Zhang, C., Duan, J., He, Z., Yang, L., Yang, S., Zhang, Z., … Wang, J. (2021). The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: A prospective two-stage, two-center study. Journal of Thoracic Disease, 13(1), 343–352. https://doi.org/10.21037/jtd-21-106

Downloads

Published

2023-10-04

How to Cite

ATA, S., KESEN, O., BAYHAN, A. Z., KÖŞECİ, T., TAŞ, Z. A., BOZKURT DUMAN, B., & ÇİL, T. (2023). Efficacy of Second-Line Treatments in Lung and Extrapulmonary Neuroendocrine Carcinomas. GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES, 8(Özel Sayı), 856–863. https://doi.org/10.5281/zenodo.8404432

Issue

Vol. 8 No. Özel Sayı (2023)

Section

Articles

License

Copyright (c) 2023 GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)